Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Numeta G13
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Numeta G13 is a specialized, ready-to-use, triple-chamber parenteral nutrition (PN) emulsion developed by Baxter specifically for preterm infants. It is designed to provide a balanced supply of energy, nitrogen (amino acids), and essential fatty acids when enteral nutrition is not feasible, insufficient, or contraindicated. The system consists of three separate compartments containing a glucose solution, a pediatric amino acid solution with electrolytes, and a lipid emulsion (typically ClinOleic, based on refined olive and soybean oils). These components are mixed just prior to administration by breaking non-permanent seals between the chambers. By providing a standardized yet tailored nutritional profile, Numeta G13 helps meet the high metabolic demands of neonates while reducing the risks associated with manual compounding of PN solutions, such as contamination and calculation errors.
- Brand names
- Numeta G13Numeta G13ENumeta G13%E
- Other names
- Parenteral nutrition for preterm infantsTriple-chamber bag for neonatal parenteral nutrition
Beyond the preview
Go deeper on Numeta G13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Numeta G13.